Total revenues of $167.1 million Net product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera° Net income of $9.0 million, or $0.19 per share (basic and ...
In 2021, it was estimated that about 23% of adults living in Las Vegas, NV had arthritis. Osteoarthritis (OA), the most common form of arthritis, affects millions of people worldwide. OA symptoms can ...
See “Non-GAAP Financial Information” below. “We entered 2025 sharply focused on our 5x30 strategy and our transition into an innovative biopharmaceutical organization,” said Frank D. Lee, chief ...
--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment-- --PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world ...
Pacira BioSciences PCRX announced results from a pilot study evaluating the unique therapeutic approach of its iovera system compared to radiofrequency ablation (RFA) for chronic low back pain (CLBP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results